KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Change in Inventory (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Change in Inventory for 12 consecutive years, with -$1.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Inventory fell 512.98% year-over-year to -$1.2 million, compared with a TTM value of -$5.0 million through Dec 2025, down 233.02%, and an annual FY2025 reading of -$5.0 million, down 233.02% over the prior year.
  • Change in Inventory was -$1.2 million for Q4 2025 at Travere Therapeutics, down from -$194000.0 in the prior quarter.
  • Across five years, Change in Inventory topped out at $22.4 million in Q4 2023 and bottomed at -$3.7 million in Q1 2025.
  • Average Change in Inventory over 5 years is $2.0 million, with a median of $201500.0 recorded in 2022.
  • The sharpest move saw Change in Inventory skyrocketed 59028.95% in 2023, then crashed 512.98% in 2025.
  • Year by year, Change in Inventory stood at -$497000.0 in 2021, then soared by 92.35% to -$38000.0 in 2022, then surged by 59028.95% to $22.4 million in 2023, then crashed by 98.73% to $285000.0 in 2024, then plummeted by 512.98% to -$1.2 million in 2025.
  • Business Quant data shows Change in Inventory for TVTX at -$1.2 million in Q4 2025, -$194000.0 in Q3 2025, and $19000.0 in Q2 2025.